System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 39963403 DOI: 10.3389/fcimb.2025.1539277

Gut-brain axis mediated by intestinal content microbiota was associated with Zhishi Daozhi decoction on constipation.

Front Cell Infect Microbiol 15:1539277

Authors: Leyao Fang, Xin Yi, Junxi Shen, Na Deng, Xinxin Peng

Affiliations

  • The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China. The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China. School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.
  • The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China. School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.
  • The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China. The Domestic First-class Discipline Construction Project of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.

Abstract

Background

Constipation is a common digestive system disorder, which is closely related to the intestinal flora. Zhishi Daozhi decoction (ZDD) is a traditional Chinese medicine prescription used to treat constipation caused by indigestion. This study is to evaluate the efficacy of ZDD in treating constipation and to elucidate the underlying mechanism.

Methods

In this study, Kunming mice were administered a high-protein diet (HFHPD) and loperamide hydrochloride injections to induce constipation. The mice then received varying doses (2.4, 4.7, and 9.4 mg/kg) of ZDD for seven days. Following the sampling process, we measured fecal microbial activity. The levels of 5-hydroxytryptamine (5-HT), vasoactive intestinal peptide (VIP), and aquaporin-3 (AQP3) were quantified using enzyme-linked immunosorbent assay. Changes in the gut microbiota were evaluated through 16S rRNA gene sequencing. Additionally, we investigated the correlation between specific microbiota features and the levels of 5-HT, VIP, and AQP3.

Results

The fecal surface of the mice in the model group (CMM) was rough and dry. The stool of mice in the low-dose ZDD group (CLD), medium-dose ZDD group (CMD), and high-dose ZDD group (CHD) exhibited a smoother texture, closely resembling that of the normal group (CNM). 5-HT levels in the CMM group were significantly lower than in the CNM, CLD, and CHD. VIP levels in the CMD were lower than in the other four groups, and AQP3 levels in CMM showed a decreasing trend. The fecal microbial activity of the CMM group was significantly higher than that of the other groups. Diversity analysis indicated that CMD and CHD treatments were more effective in restoring the intestinal microbiota structure. Potential pathogenic bacteria, including , , , and were enriched in CMM. In contrast, beneficial bacteria such as , , and were more prevalent in the CLD, CMD, and CHD. Correlation analysis revealed that and were positively correlated with VIP, while showed a negative correlation with 5-HT.

Conclusions

Constipation induced by HFHPD and loperamide hydrochloride disrupts the structure of the intestinal microbiota. ZDD appears to alleviate constipation, potentially through mechanisms linked to the brain-gut axis and its interaction with the intestinal microbiota. Among the treatment groups, the medium dose of ZDD demonstrated the most effective results.

MeSH

Genes, Rrna, Loperamide, Brain, Constipation, Cell Biology, Therapeutics, Bacteria, Microbiota